Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

38.16USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$38.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
318,625
52-wk High
$68.05
52-wk Low
$30.00

Select another date:

Thu, Aug 23 2018

BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis

* GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval

* Shares fall as much as 12 pct (Adds details from conference call, analyst comments; updates share move)

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

Select another date: